X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The results showed that CODA's lead receptor AAV Based Therapy, and activator drug significantly reduces seizure frequency in two different models of focal epilepsy - electrical seizure threshold and kainic acid induction.
Lead Product(s): AAV-based Therapy,Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
The results showed efficacy for AAV Vector based gene therapy approach in controlling spontaneous seizures in a model system that replicates many features of human temporal lobe epilepsy can control focal seizures in vivo.
Lead Product(s): AAV Vector Based Gene Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2021
Details:
Funding will be used to support CODA's plans to evaluate and advance the Company's unique receptor-ligand pairs toward the clinic for the treatment of neuropathic pain.
Lead Product(s): AAV Vector based gene therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Funding November 10, 2020
Details:
Strategic partnership supports CODA's efforts to develop gene-therapy mediated treatments and cures for trigeminal neuralgia and related neuropathic pain.
Lead Product(s): Aav Vectors
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Facial Pain Research Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
